Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT05594342
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- The Young Investigator Group of Cardiovascular Research
- Registry
-
NCT05594342
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Unknown status
Technical summary
Registry record NCT05594342. Randomized; no masking; primary purpose treatment. Start 2022-07-01 (actual); primary completion 2023-01-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
- Acronym
- IVA-CS
- Condition
- Heart Failure
- Condition
- Cardiogenic Shock
- Condition
- Ischemic Heart Disease
- Intervention (Drug)
- Ivabradine 7.5Mg Tab
- Intervention (Drug)
- DOBUTamine Injectable Solution
- Lead sponsor
- The Young Investigator Group of Cardiovascular Research
Record details
- Record id
cardio:ct-nct05594342- Content hash
f4dd73cf40468fc84a1a0efecb59e904eaed91b4f761a5aedbcd090813594629